Every 8-K that HeartSciences Inc. Warrant (HSCSW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HSCSW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HSCSW filings page.
HeartSciences Inc. announced that the FDA granted 510(k) clearance for its MyoVista wavECG device as a 12-lead resting electrocardiograph. The clearance covers acquisition and interpretation of ECG signals from adult and pediatric patients in hospitals and healthcare facilities, with interpretive statements provided to clinicians on an advisory basis; it does not include an AI-ECG algorithm. HeartSciences says it does not intend to commercialize the device without a cleared AI-ECG algorithm and has no commercialization timeline. Its commercial focus remains MyoVista Insights, and it intends to evaluate options for the device and related intellectual property. The device and AI-ECG submissions were separated following updated American Society of Echocardiography guidance on assessing left ventricular diastolic dysfunction.
HeartSciences expects its proposed business combination with Fortitude Mining Holdings, Inc. to close in Q4 calendar 2026, subject to customary closing conditions, including approval by HeartSciences shareholders.
HeartSciences Inc. and Front Range Ventures LLC amended the loan agreement and secured note, extending the maturity date to the earlier of two business days after closing of the proposed business combination with Fortitude Mining Holdings, Inc., or January 29, 2027. The original loan was for $500,000, and the note accrued interest at 12% per annum, compounded annually.
Accrued unpaid interest as of September 30, 2026 is payable on or before that date; interest accruing thereafter is due at maturity. HeartSciences may repay all or part of the outstanding principal before maturity in amounts of at least $50,000. Each repayment is applied first to accrued interest and then to principal.
HeartSciences Inc. (HSCS) reports leadership changes at Fortitude Mining Holdings, its proposed merger partner, and highlights Fortitude’s current operating scale. Fortitude’s board appointed Jaime Leverton as Chief Executive Officer and director effective September 21, 2026, while Andrea Childs transitions from CEO and director to Chief Operating Officer. The companies state that, following the closing of the previously announced business combination, HeartSciences is expected to be renamed Fortitude Mining Group, Inc., with Leverton serving as CEO and a board member. Fortitude’s press release notes that in the six months ended June 30, 2026 it mined a substantial share of Zcash network production and generated meaningful revenue, and that the proposed transaction is expected to close in the fourth quarter of 2026, subject to customary conditions including HeartSciences shareholder approval.
HeartSciences Inc. (HSCS) reported fiscal first quarter 2027 results and gave an update on its pending all-stock merger with Fortitude Mining Holdings. The Fortitude transaction, announced in June 2026, is described as continuing to progress, with closing expected in Q4 2026, subject to customary conditions including HeartSciences shareholder approval.
For the quarter ended July 31, 2026, HeartSciences reported no meaningful revenue, a loss from operations of $2.9 million versus $1.9 million a year earlier, and a net loss of $3.2 million versus $2.1 million. The operating loss included about $0.5 million in additional legal and professional fees related to the Proposed Transaction, $0.5 million of non-cash share-based compensation triggered by the passing of Mark Hilz, and a $0.3 million inventory reserve for the MyoVista wavECG device. As of July 31, 2026, shareholders’ deficit was $2.0 million.
The company is concentrating its commercial efforts on the MyoVista Insights cloud-based ECG management and AI orchestration platform, has signed its first U.S. commercial agreements, and was selected as the AI-ECG delivery platform for a major European reference center. HeartSciences does not currently plan to commit significant additional resources to commercializing the MyoVista wavECG device and has reserved against related inventory. Liquidity actions after quarter end included approximately $1.0 million of common stock purchased by Fortitude, about $1.2 million of net proceeds from at-the-market sales, and the exchange of $200,000 of note principal into equity; the Fortitude merger exchange ratio was not adjusted for these issuances.
HeartSciences Inc. (HSCS) reported, via a Regulation FD disclosure, second‑quarter 2026 financial and operating highlights from proposed merger partner Fortitude Mining Holdings. Fortitude generated $20.9 million in revenue and $8.5 million in Adjusted EBITDA for the quarter, mining about 33,646 ZEC at an average hash rate of 4.0 GSol/s with more than 60 MW of controlled power capacity across seven sites.
Fortitude and HeartSciences have a definitive merger agreement, with the business combination expected to close in H2 2026, subject to HeartSciences shareholder approval and other conditions. On August 12, 2026, Fortitude invested about $1,000,000 in HeartSciences through a private placement of 411,522 HSCS shares at $2.43 per share, a 22% premium to the then‑closing price, and now holds approximately 9.4% of HeartSciences’ outstanding common stock. The investment is described as supporting HeartSciences’ operating expenses ahead of the contemplated merger.
The disclosure emphasizes that communications regarding the proposed transaction are solicitation material, urges shareholders to read the proxy materials on file with the SEC, and includes extensive forward‑looking‑statement and digital‑asset risk language, noting that the transaction may not close and that Fortitude’s business is exposed to Zcash and broader cryptocurrency volatility.
HeartSciences Inc. (HSCS) reported that Fortitude Mining Holdings, Inc. invested approximately $1.0 million through a private placement completed on August 12, 2026. Fortitude purchased 411,522 shares of HeartSciences common stock at $2.43 per share, a 22% premium to the closing market price on the purchase date.
The new shares are ordinary voting common stock with no special rights, and the investment lifts Fortitude’s stake to about 9.4% of HeartSciences’ outstanding shares. The company states that the cash investment provides additional working capital and strengthens its balance sheet ahead of the expected closing of the proposed business combination between HeartSciences and Fortitude, which is anticipated in the second half of the current calendar year, subject to customary conditions, including shareholder approval. The exchange ratio under the existing merger agreement is unchanged, and no extra merger consideration will be issued to Fortitude in respect of this investment.
HeartSciences Inc. (HSCS) entered into a Subscription Agreement with Fortitude Mining Holdings, Inc. for a private placement of 411,522 shares of common stock at $2.43 per share, raising gross proceeds of approximately $1.0 million.
The PIPE Investment is intended to fund operating expenses before the expected closing of HeartSciences’ proposed business combination with Fortitude under the June 23, 2026 Merger Agreement. Following this investment, Fortitude owns approximately 9.4% of HeartSciences’ issued and outstanding common stock. The unregistered shares were issued in reliance on the Securities Act Section 4(a)(2) exemption and are not subject to the Merger Agreement’s Exchange Ratio.
HeartSciences Inc. reported receiving a notice from Nasdaq that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. In its Form 10-K for the year ended April 30, 2026, the company reported stockholders’ equity of $226,060 and also did not meet the alternative market value or net income standards.
The company’s common stock and public warrants remain listed while it works on regaining compliance. HeartSciences has 45 calendar days, until September 18, 2026, to submit a compliance plan and, if accepted, could receive up to 180 days from August 4, 2026, or until January 31, 2027, to evidence compliance. Management is evaluating options, including consummating its previously announced all-stock merger with Fortitude Mining Holdings, Inc., and notes that any suspension or delisting could reduce liquidity, market price, access to equity financing, ability to grant equity incentives, and ability to complete the proposed transaction.
HeartSciences Inc. reported selected results for the fiscal year ended April 30, 2026 and outlined progress on its proposed all-stock business combination with Fortitude Mining Holdings, Inc., a vertically integrated digital asset mining platform anchored in Zcash. For Fiscal 2026, the company reported no meaningful revenue, cash and cash equivalents of approximately $1.7 million and shareholders’ equity of $0.2 million.
The company described the period as one of “transformational change,” citing the full commercial launch of its MyoVista Insights healthcare IT platform, deployment contracts with healthcare institutions, and submission of its MyoVista wavECG device to the FDA for 510(k) clearance, which is under review. A preliminary proxy statement has been filed describing the Fortitude transaction and an authorization for the board to implement, if needed to support Nasdaq listing requirements for the combined company, a reverse stock split within a range of 1-for-2 to 1-for-5. Forward-looking disclosures highlight uncertainties around completing and integrating the transaction and exposure to digital asset market volatility.
HeartSciences Inc. is progressing its Agreement and Plan of Merger with Fortitude Mining Holdings by providing audited Fortitude financials and unaudited pro forma combined information. Fortitude operates a digital asset mining business focused on Bitcoin, Zcash and other proof‑of‑work assets.
For the year ended December 31, 2025, Fortitude generated total revenues of $89,497 (in thousands) and recorded a net loss of $12,676 (in thousands). As of that date it reported total assets of $72,792 (in thousands), including cash of $9,995 (in thousands), property and equipment of $39,646 (in thousands) and digital assets of $3,413 (in thousands). Mining revenues from a related‑party pool operator accounted for $58,091 (in thousands) of 2025 revenues.
For the three months ended March 31, 2026, Fortitude reported total revenues of $19,225 (in thousands) and a net loss of $4,649 (in thousands). The company completed the Aurora, Nebraska mining asset acquisition for allocated consideration of $7,889 (in thousands), adding strategic power contracts and infrastructure, and concluded that existing resources should support at least 12 months of operations.
HeartSciences Inc. entered into Amendment No. 1 to its June 23, 2026 Agreement and Plan of Merger with Fortitude Mining Holdings, Inc., Fortitude Mining HoldCo, LLC and Cordis Acquisition, LLC. The amendment replaces the form of the A&R LLC Agreement to clarify certain redemption mechanics.
The amendment also replaces the form of the Parent New Charter to provide for a proposed amendment to the requirements for HeartSciences shareholder action by written consent. HeartSciences plans to file a proxy statement with the SEC and mail it to stockholders in connection with the transactions contemplated by the amended merger agreement.
HeartSciences Inc. filed its Annual Report on Form 10-K for the fiscal year ended April 30, 2026 and highlighted a previously announced Merger Agreement providing for a proposed business combination with Fortitude Mining Holdings, Inc., an institutional-scale, vertically integrated venture mining platform anchored in Zcash and currently wholly owned by Digital Currency Group.
The company plans to file a preliminary proxy statement with the SEC shortly to seek shareholder approval for the transactions described in the Merger Agreement and then issue its fiscal 2026 earnings release and a business update, which it currently expects early the following week. Management states it believes the proposed Fortitude transaction offers a significant opportunity for shareholders by providing continued ownership in a business operating at scale and generating meaningful revenue, while allowing HeartSciences’ MyoVista Insights AI-ECG technology to continue advancing with greater focus.
HeartSciences Inc. reports changes to the employment arrangements for Chief Financial Officer Danielle Watson in connection with its planned merger with Fortitude Mining HoldCo, LLC. An amendment to her employment agreement adds severance protections if she is terminated without Cause or resigns for Good Reason, including six months of base salary, up to six months of company-paid or reimbursed COBRA premiums, and acceleration of unvested equity awards granted before the merger closing, subject to a release of claims.
The compensation committee also granted Ms. Watson an equity award of 25,000 restricted stock units under the 2023 Equity Incentive Plan, effective July 7, 2026 and subject to the merger closing. These RSUs vest in four equal installments every three months beginning three months after closing, fully vesting one year after closing, with full acceleration upon certain terminations without Cause, resignations for Good Reason, or a Change of Control other than the merger.
HeartSciences Inc. entered into a Merger Agreement under which its subsidiary will merge with Fortitude Mining HoldCo, LLC, making Fortitude the surviving company and HeartSciences the sole managing member after closing, subject to customary conditions and stockholder approval.
In connection with the planned transaction, CEO Andrew Simpson’s employment agreement was amended, and he received a retention equity award of 425,000 restricted shares of common stock that were issued on June 22, 2026. These shares are non-voting until they vest and will vest over one year after closing, with full acceleration upon certain terminations without cause, constructive termination, or a separate change of control.
The Compensation Committee also confirmed a $250,000 cash bonus for Mr. Simpson payable at closing of the transaction and approved a $50,000 discretionary cash bonus for CFO Danielle Watson tied to the proxy filing and closing. The Board approved an amendment to the 2023 Equity Incentive Plan to increase the share reserve by 475,000 shares, subject to shareholder approval, and conditionally expanded the Board from five to nine directors, with Andrea Childs and Erik Ellingson designated to become CEO and CFO at the effective time.
HeartSciences Inc. is entering an all-stock merger with Fortitude Mining Holdings to create a Nasdaq-listed Zcash-focused mining company under the Fortitude brand. Fortitude’s management will lead the combined company, which is expected to trade under the ticker TUDE, while Digital Currency Group is expected to remain the largest and controlling shareholder.
For full year 2025, Fortitude generated approximately $90 million in gross revenue and $20 million in Adjusted EBITDA, and held about $13 million in cash and digital assets at year end. Through April 30, 2026, Fortitude produced approximately 51,785 ZEC, with a direct cash mining cost per coin of about $70 and a targeted pathway toward $40.
Fortitude currently owns and operates 48 megawatts of data center capacity across six U.S. sites and is targeting approximately 80 megawatts of total capacity by year end 2026. Illustrative scenarios presented on the call suggest Adjusted EBITDA of over $50 million at a Zcash price of $500 and over $120 million at $1,000. The transaction has been unanimously approved by both boards and is expected to close in the second half of 2026, subject to customary conditions including HeartSciences shareholder approval and completion of SEC proxy processes.
HeartSciences Inc. is pivoting its business through an all-stock merger with Fortitude Mining Holdings, a Zcash-focused digital asset miner. Fortitude equityholders are expected to receive about 95.0% of HeartSciences’ post-closing equity, leaving existing HeartSciences shareholders with roughly 5.0%.
The deal uses an Up‑C style structure with a new non-economic Class V voting stock and Surviving Company non‑voting units that can later be redeemed for Class A shares or cash. Closing is targeted for the second half of 2026, subject to shareholder approvals, Nasdaq listing conditions and other customary closing conditions. Fortitude’s management, led by CEO Andrea Childs, will take over the combined company, which is expected to rebrand as Fortitude and trade on Nasdaq under the ticker “TUDE.”
HeartSciences Inc. reported voting results from its Annual Meeting of Stockholders. Shareholders representing 1,973,863 shares, or 57% of the 3,477,698 shares entitled to vote as of March 6, 2026, were present, establishing a quorum.
Shareholders elected Andrew Simpson as a Class III director, approved an increase in shares reserved under the 2023 Equity Incentive Plan to 1,250,000 shares plus a formula-based annual add-on, and ratified Haskell & White LLP as independent auditor for the fiscal year ending April 30, 2026. A charter amendment to add limited officer exculpation did not obtain the required majority, while an adjournment proposal to allow additional proxy solicitation was approved.
HeartSciences Inc. reported the death of Mark Hilz, its Chief Operating Officer, Corporate Secretary and a board member, who passed away on April 1, 2026 at age 67 after a period of illness. He had served on the Board since 2013 and as COO and Corporate Secretary since March 2022.
The company states it does not expect to hire a new Chief Operating Officer in the foreseeable future, noting that its MyoVista Insights™ software platform has been launched and the MyoVista® wavECG™ device has been submitted to the U.S. Food and Drug Administration for 510(k) premarket clearance. HeartSciences does not anticipate any changes to its business, operations or planned commercialization of the MyoVista Insights platform as a result of his passing.
HeartSciences Inc. reported fiscal third-quarter 2026 results and shared a business update. The healthcare IT company is focused on commercializing its MyoVista Insights ECG platform and has submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance, an important regulatory milestone.
The company reported no meaningful revenue for the quarter as it continues investing in commercialization. As of January 31, 2026, it held approximately $3.4 million in cash and cash equivalents and $2.7 million in shareholders’ equity. Full financial details are available in its Form 10-Q for the same period.
HeartSciences Inc. entered into a Note Purchase Agreement with Streeterville Capital, LLC, issuing an unsecured promissory note for $3,605,000, which includes a $600,000 original issue discount and $5,000 of transaction expenses, for gross cash proceeds of $3,000,000. The Note carries 12% annual interest, matures 18 months after issuance, and allows Streeterville, starting six months after issuance, to require monthly redemptions of up to $405,000. If the outstanding balance has not been reduced by at least $1,250,000 by the 12‑month anniversary, the outstanding balance at that time automatically increases by 5%. The Note and related agreement include customary covenants, events of default, potential default interest up to 18% (or the legal maximum), and indemnification of Streeterville, and were issued as an unregistered private placement under Section 4(a)(2) and Rule 506.
HeartSciences Inc. reports that it has regained compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement, which calls for at least $2.5 million in stockholders’ equity for companies on The Nasdaq Capital Market. Nasdaq’s Listing Qualifications Staff notified the company on September 16, 2025, that the issue is resolved and the matter is now closed. HeartSciences had previously submitted a plan to Nasdaq explaining how it would regain and maintain compliance after falling below the required equity level.
HeartSciences Inc. filed a current report to furnish a press release covering its financial and operating results for the quarter ended July 31, 2025, along with other business updates. The press release is included as Exhibit 99.1 and is incorporated by reference in this report. The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other securities filings.
HeartSciences Inc. reports progress on its Regulation A offering and a related debt exchange that change its mix of cash, debt, and equity. The company’s qualified Form 1-A allows an offering of up to 4,285,714 units at $3.50 per unit, for a maximum of $15,000,000. Each unit includes one share of Series D preferred stock and a warrant to buy one share of common stock at $5.00 per share.
As of August 22, 2025, HeartSciences has received $5.2 million of gross proceeds, issuing 1,484,440 units. Holders of 979,851 Series D preferred shares have already converted them into 979,851 common shares. Separately, the company has exchanged $1,655,000 of an unsecured promissory note for 461,572 common shares, reducing that note’s principal. After these transactions, 2,535,066 common shares are issued and outstanding as of August 22, 2025.